Showing results (31-40 of 38) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Nature Medicine|October 27, 2022
Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trialLucia Bailón, Anuska Llano, Samandhy Cedeño, et al.AIDS (London, England)|April 2, 2019
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trialsSamir K Gupta, Frank A Post, José R Arribas, et al.The New England Journal of Medicine|July 29, 2026
Phase 3 Trial of Weekly Oral Islatravir-Lenacapavir for HIV-1 TreatmentJürgen K Rockstroh, Moti N Ramgopal, Adrian Curran Fàbregas, et al.The New England Journal of Medicine|May 28, 2020
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19Jason D Goldman, David C B Lye, David S Hui, et al.Nature Communications|January 21, 2025
Time to HIV viral rebound and frequency of post-treatment control after analytical interruption of antiretroviral therapy: an individual data-based meta-analysis of 24 prospective studiesJesper D Gunst, Jesal Gohil, Johanthan Z Li, et al.JAMA|August 22, 2020
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical TrialChristoph D Spinner, Robert L Gottlieb, Gerard J Criner, et al.The Journal of Clinical Investigation|November 13, 2012
HERV-K-specific T cells eliminate diverse HIV-1/2 and SIV primary isolatesR Brad Jones, Keith E Garrison, Shariq Mujib, et al.Nature Communications|March 4, 2025
Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trialLucia Bailón, José Moltó, Adrian Curran, et al.Pageof 4